Mallinckrodt Plc - Company Profile
Powered by 
All the data and insights you need on Mallinckrodt Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Mallinckrodt Plc Strategy Report
- Understand Mallinckrodt Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Mallinckrodt Plc (Mallinckrodt) develops, produces, markets, and distributes specialty pharmaceutical products and therapies. The company offers branded pharmaceutical products for autoimmune and rare diseases in specialty areas such as rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers immunotherapy, oncology and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. It offers specialty generic drugs and active pharmaceutical ingredients. Mallinckrodt markets branded products directly to physicians, specialty pharmacies, hospitals and ambulatory surgical centers; and also distributes branded and generic products through a network of drug distributors, specialty pharmaceutical distributors and retail pharmacy chains, among others. It has facilities in the US, Ireland, Japan and other countries. Mallinckrodt is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
College Business & Technology Park, Cruiserath, Blanchardstown, Dublin
Website
www.mallinckrodt.com
Telephone
353 1 8207940
No of Employees
2,800
Industry
Pharmaceuticals and Healthcare
Revenue (2021)
$2.2B
Mallinckrodt Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Specialty Brands: |
| Repository Corticotropin Injection |
| Nitricoxide |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In November, the company completed its financial restructuring and emerged from bankruptcy. |
| 2023 | Plans/Strategy | In September, the company announced its plans to sell its business units. |
| 2023 | Bankruptcy Filing | In August, the company filed for its second bankruptcy in the US. |
Competitor Comparison
| Key Parameters | Mallinckrodt Plc | Merck & Co Inc | Bayer AG | Eli Lilly and Co | Johnson Matthey Plc |
|---|---|---|---|---|---|
| Headquarters | Ireland | United States of America | Germany | United States of America | United Kingdom |
| City | Dublin | Kenilworth | Leverkusen | Indianapolis | London |
| State/Province | - | New Jersey | Nordrhein-Westfalen | Indiana | England |
| No. of Employees | 2,800 | 69,000 | 100,873 | 39,000 | 12,666 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul M. Bisaro | Chairman | Executive Board | 2022 | 62 |
| Sigurdur O. Olafsson | President; Director; Chief Executive Officer | Executive Board | 2022 | 54 |
| Bryan M. Reasons | Executive Vice President; Chief Financial Officer | Senior Management | 2019 | 55 |
| Mark Tyndall | Executive Vice President; Corporate Secretary; Chief Legal Officer | Senior Management | 2022 | 47 |
| Kassie Harrold | Executive Vice President; Chief Compliance Officer | Senior Management | - | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward